RedChip

FibroBiologics Inc. (Nasdaq: $FBLG): Join the Live Investor Webinar on Thursday, November 19, at 4:15 p.m. ET RedChip will host a live investor webinar with FibroBiologics CEO Pete O’Heeron and CFO Jason Davis. FibroBiologics is developing off-the-shelf cell therapies made from fibroblasts, the body’s main tissue-repair cells, for chronic diseases. Management will give an update on its lead program, CYWC628, which is in a Phase 1/2 trial for diabetic foot ulcers. They will also cover the rest of the pipeline, including programs in psoriasis, multiple sclerosis and degenerative disc disease, and the company’s portfolio of more than 325 issued and pending patents. A live Q&A will follow, and questions can be sent ahead of time to FBLG@redchip.com. Register for free: redchip.news/4iPlnBw

Alliance Entertainment Holding Corporation (Nasdaq: $AENT): Fiscal Q1 2027 Revenue Up 10% and GAAP Net Income Up 56% on Strong Demand for Physical Media and Collectibles Alliance Entertainment reported first-quarter fiscal 2027 revenue of $278.8 million, up 10% from a year earlier, while GAAP net income rose 56% to $7.6 million. Growth came from physical movies, vinyl, CDs and collectibles, with collectibles revenue nearly doubling. The movie business got a lift from the company’s exclusive distribution deals with Paramount and Amazon MGM Studios. Gross margins improved, and interest costs fell by about half after last year’s refinancing. CEO Jeff Walker said fans who stream music and movies still want physical products they can own and collect. Management will host a conference call today at 4:30 p.m. ET. Full press release: redchip.news/4AsoKFB

FibroBiologics Inc. (Nasdaq: $FBLG): Fibroblast Patent Portfolio Grows to 170 Issued Patents and More Than 325 Issued and Pending Worldwide FibroBiologics, a clinical-stage biotech company developing therapies for chronic diseases using fibroblasts, gave an update on its intellectual property portfolio. Fibroblasts are the most common cells in connective tissue. The company now holds 170 issued patents, up from 124 at the end of 2025, and more than 325 issued and pending worldwide across more than 50 patent families. Patents granted in 2026 include U.S. patents covering wound healing, type 1 diabetes, osteoporosis, cachexia and degenerative disc disease. The company also received European patents on enhancing fibroblast therapeutic activity and using fibroblasts to deliver tumor-inhibiting agents. The portfolio covers both what fibroblast therapies treat and how they are made, including methods for producing three-dimensional fibroblast spheroids at scale. More than 150 applications are still pending. Full press release: redchip.news/4eZGLD2

⏰ One Week Away: FibroBiologics ($FBLG) Live Investor Webinar, Thursday, November 19 at 4:15 PM ET The FibroBiologics webinar is one week away. The company is building a platform around fibroblasts, cells that are abundant, easy to grow and naturally drawn to sites of injury and disease. Management will walk through how that platform applies across chronic disease, regenerative medicine and oncology. 📈 What’s driving the story: In a 12-week rabbit model of degenerative disc disease, its FSdC spheroids reached a disc height index of 80.7% versus 71.8% in controls (p<0.05) The FSdC spheroid group kept a significantly higher disc height index than the other treatment groups throughout the study A new European patent covers fibroblasts modified to home to tumors and deliver oncolytic viruses and other anti-cancer payloads In a mouse melanoma model described in the patent, virus-carrying fibroblasts significantly inhibited tumor growth, while the virus alone did not More than 270 patents issued and pending across the pipeline Secure your seat today to hear management’s view of the road ahead. 🔗 Register here: redchip.news/4fchsh2 #FBLG #FibroBiologics #CellTherapy #Fibroblasts #RegenerativeMedicine #WoundHealing #Biotech #NasdaqStocks #InvestorWebinar #SmallCapInvesting

RedChip is proud to sponsor the DealFlow Discovery Conference, January 26 to 28, 2027, at The Borgata in Atlantic City. Join 1,250+ attendees and 200 presenting companies, from public microcaps to late-stage pre-IPO companies, for unlimited 1-on-1 investor meetings, issuer workshops and plenty of networking.

Bimergen Energy Corporation (NYSE American: $BESS): Management to Meet Partners and Capital Providers at RE+ 2026 as It Advances 2.0 GW Battery Storage Portfolio Bimergen Energy Corporation announced that members of its management team plan to attend RE+ 2026, North America’s largest clean energy industry event, from November 16 to 19 at the Las Vegas Convention Center. Management plans to meet with joint venture partners, battery manufacturers, project lenders and tax equity investors. The team will also look for new relationships with technology providers, developers and institutional capital partners. Bimergen reports a development portfolio of 33 battery energy storage projects totaling about 2.0 gigawatts across U.S. electricity markets. The projects are at varying stages of development. The company expects its RE+ participation to support its work with technology and capital partners as it moves projects toward commercialization. Full press release: redchip.news/4fnt0hy

Venu Holding Corporation (NYSE AMERICAN: $VENU): CEO J.W. Roth Named to Billboard’s 2026 Touring Power Players List for Second Straight Year Venu Holding Corporation announced that Founder, Chairman and CEO J.W. Roth has been named to Billboard’s 2026 Touring Power Players list, his second year in a row. Billboard’s editors choose the list each year to recognize the executives moving the touring business forward. Since founding VENU in 2017, Roth has built a portfolio of premium music and hospitality venues across Colorado, Georgia, Oklahoma, Tennessee and Texas. The portfolio includes Ford Amphitheater, Regent Bank Amphitheater and Sunset Amphitheaters, and a nationwide expansion is underway. This year’s recognition adds to Roth’s VenuesNow All-Star honors in 2022, 2025 and 2026 and his CEO of the Year award at the Southern Colorado Business Forum & Digest’s 2026 Best in Business Awards. Full press release: redchip.news/48Obgs2

Join Our Investor LIVE Q&A 60 Degrees Pharmaceuticals- LIVE NOW xitter.twitterapi.xyz/i/broadcasts/2JQPYpjKR…

Join Our Investor LIVE Q&A 60 Degrees Pharmaceuticals- LIVE NOW xitter.twitterapi.xyz/i/broadcasts/2KoOjMAay…

⏳ Starting in 30 Minutes: 60 Degrees Pharmaceuticals (NASDAQ: SXTP) Live Investor Webinar at 4:15 PM ET Last chance to register. In 30 minutes, 60P management goes live to discuss how the company is using an FDA-approved drug to target babesiosis, a tick-borne infection with no approved treatment and a growing patient population. Join now to hear the strategy firsthand and get your questions answered live. ⚡ Why you should be in the room: ARAKODA® is FDA-approved, with more than 1,100 patient exposures across 8+ published trials No FDA-approved treatments currently exist for babesiosis An initial estimate of up to 380,000 addressable U.S. patients each year and up to $245M in potential peak annual sales Three babesiosis studies are expected to yield initial data in late 2026 A management team that has together led six clinical trials Register now and join us live at 4:15 PM ET. 🔗 Register here: redchip.news/4iA1YV5 #SXTP #60DegreesPharma #Babesiosis #LymeDisease #InfectiousDisease #Biotech #BiotechStocks #NasdaqStocks #InvestorWebinar #SmallCapInvesting

BioVie (Nasdaq: $BIVI): Invited to Give Two Oral Presentations on Bezisterim in Parkinson’s Disease at AD/PD 2027 BioVie has been invited to give two oral presentations on its Phase 2 SUNRISE-PD trial of bezisterim at the AD/PD 2027 International Conference on Alzheimer’s & Parkinson’s Diseases in Barcelona on March 20, 2027. The presentations will share new findings, including exploratory analyses of bezisterim’s effects on markers of disease progression and the use of biomarkers to select patients. In the 57-patient trial, patients with higher baseline inflammation saw statistically significant improvements in both motor and non-motor symptoms. Across all patients, those on bezisterim were 6.25 times more likely than placebo patients to achieve clinically meaningful improvement. Full press release: redchip.news/48cdzF6

Nova Minerals (NYSE American: $NVA): Confirms 216,000 tpa Processing Capacity, Advancing Alaska’s Critical Minerals Hub An engineering assessment confirmed that Nova Minerals’ newly acquired processing plant equipment, delivered to Port MacKenzie, Alaska, has approximately 216,000 tonnes per year of front-end crushing, grinding and concentration capacity. Nova’s Phase 1 refinery, funded by a $43.4 million Department of War award, targets up to 600 tonnes per year of refined antimony, with military-grade production expected in 2027. Using the existing plant and adding downstream refining equipment, modeling shows potential output of about 9,400 to 20,000 tonnes per year, depending on feed grade. The plant could also process tungsten, gallium and other critical minerals and serve as a regional toll-processing hub for third-party producers. Full press release: redchip.news/4BQrGxz

Gunnison Copper (NYSE American: $GUNN): Drilling Confirms High-Grade Copper-Zinc-Silver at Strong & Harris, Including 40 Feet of 5.1% Copper and 12.0% Zinc Gunnison Copper reported initial assay results from its 2026–2027 drilling program in southern Arizona. At the high-grade Strong & Harris satellite deposit, hole SHM-2 intersected 40 feet grading 5.15% copper, 11.99% zinc and 16.38 g/t silver, within a broader 311-foot interval grading 1.39% copper and 2.29% zinc. That confirms a high-grade zone already in the company’s resource model. At the flagship Gunnison Project, holes returned long copper intervals, including 790 feet grading 0.46% copper. About 20% of the planned 138,000-foot program is complete, and Gunnison is running flotation tests on a potential processing route to recover zinc and silver alongside copper. Full press release: redchip.news/4ev1E8V

Alliance Entertainment (Nasdaq: AENT) led the latest funding round for ArtPics, a brand built on Alliance’s Endstate authentication technology. With it, Alliance planted another stake across two of the fastest growing markets: a global art market where sales rose to $59.6B in 2025 (Art Basel & UBS), and a memorabilia and trading card market valued at $70B today and expected to reach $393 billion by 2036 (Market Decipher). “We’ve integrated Endstate’s patented NFC technology to authenticate and protect every original ArtPics Fine Art trading card,” said founder and CEO Gareb Shamus. “As collecting and secondary markets grow worldwide, this will play an integral role in the future of collectibles.” @artpicscard @alliance.entertainment #RedChip #AENT #AllianceEntertainment #Art #Collectibles Read the Full Release: redchip.news/4kH1Bur

🚨 TODAY: 60 Degrees Pharmaceuticals (NASDAQ: SXTP) Live Investor Webinar at 4:15 PM ET The 60 Degrees Pharma investor webinar is today. This afternoon, management will present an FDA-approved product already on the market alongside a clinical program in babesiosis, a growing tick-borne disease with no approved therapy. Bring your questions on ARAKODA® sales growth, the babesiosis studies and the path to an FDA submission. 📋 What’s on the table today: ARAKODA® is available in the U.S. through a network of major national distributors The 2026 commercial plan doubles inside sales capacity and adds enhanced digital marketing New patient-access channels include a GoodRx partnership and a travel-focused telehealth channel with Runway Health No Babesia infection was detected in the first patient to complete therapy in the relapsing babesiosis study Initial babesiosis clinical data is expected in late 2026 Register now to join the live presentation this afternoon. 🔗 Register here: redchip.news/4iA1YV5 #SXTP #60DegreesPharma #Babesiosis #LymeDisease #InfectiousDisease #Biotech #BiotechStocks #NasdaqStocks #InvestorWebinar #SmallCapInvesting #RedChip

✈️ The future of transportation is taking off. Horizon Aircraft (NASDAQ: $HOVR) is developing vertical takeoff and landing (VTOL) aircraft designed to change how people and goods move. The company previously received a U.S. Air Force grant that ranked its VTOL technology among the most capable in the world, and it has more than $1 billion in commercial agreements as it moves toward commercialization. 👉 Learn more: redchip.news/48FeM86 #HOVR #HorizonAircraft #eVTOL #VTOL #Aviation #AdvancedAirMobility #Aerospace #Nasdaq #SmallCapStocks

Anixa Biosciences (NASDAQ: ANIX) 100% of vaccinated mice stayed cancer-free in preclinical mouse studies #Anixa #Biosciences #Cancer #Vaccine #RedChip

🧬 Recently covered by RedChip: $40M+ Revenue Diagnostics Company Valued at Roughly $6M Advances CGM+ and Enters AI Data Center Cooling Trinity Biotech (Nasdaq: TRIB) generates roughly $40 to $50 million in annual revenue from a global diagnostics portfolio built over more than 30 years, yet the market values the company at approximately $6 million. A new RedChip article examines the turnaround underway since new management took over in late 2023 and the two larger markets the company is now pursuing. In the first quarter of 2026, revenue rose 43% year over year to $10.8 million, and gross margin improved to 35.4% from 25.2%, as the company consolidated manufacturing and shifted production to lower-cost locations. 📌 Why Investors Should Be Watching: - CGM+ clinical data: In pre-pivotal testing covering more than 5,000 hours of sensor wear, Trinity reported that its multi-sensor platform identified compression-induced false low readings, a known limitation of glucose-only monitors - Trinovium: The new subsidiary applies Trinity's high-purity fluid manufacturing to AI data center liquid cooling, a market projected to grow from approximately $4 billion in 2026 to $27 billion by 2033, and has announced a collaboration with Echelon Data Centres - Diagnostics volume: Orders for more than two million TrinScreen HIV tests add volume to the core business as the manufacturing transition progresses CGM+ still has pivotal clinical development and regulatory submissions ahead, and Trinovium has yet to reach commercialization, but both are being built on technology and infrastructure Trinity already owns. Read the full article: redchip.news/4iR1V9g Trinity Biotech is a client of RedChip. Not investment advice. Do your own due diligence. $DXCM $MDT $TNDM $ABT $SAN $PODD

BioVie ($BIVI): New Biomarker Data at NIH Workshop Help Explain Who Benefits Most from Bezisterim in Long COVID BioVie presented new biomarker findings from its Phase 2 ADDRESS-LC trial at the NIH’s RECOVER-TLC workshop, the initiative created to speed the development of Long COVID treatments. Analyzing 380 plasma biomarkers, BioVie identified two distinct patient groups with different responses to bezisterim. In highly inflamed patients, it showed a large effect on objective cognition (p=0.001). In a less-inflamed group, it was associated with improvements in fatigue and post-exertional malaise. Bezisterim also lowered neuropeptide Y, a biomarker elevated in ME/CFS and Gulf War Syndrome, by about 33%. BioVie says the findings provide a potential biological explanation for its earlier clinical results and could help target future trials to the patients most likely to benefit. More data will be presented this week at the Long COVID International Conference in Nice. Full press release: redchip.news/3WWntIt

📣 Two Days Out: 60 Degrees Pharmaceuticals ($SXTP) Live Investor Webinar, Tuesday, November 10 at 4:15 PM ET If you haven’t registered yet, now is the time. On Tuesday, management will cover both sides of the 60P story: a commercial antimalarial business that is scaling up and a babesiosis program targeting a large market with no approved treatment. It’s a direct chance to ask about the upcoming data and the commercial plan. 🎯 Key catalysts to hear about: Initial data from three babesiosis clinical studies, expected in late 2026 A regulatory strategy for an FDA submission, to be set after the data Up to $245M in potential peak annual babesiosis sales, based on initial research estimates Up to $1.1B in potential cumulative revenue through patent expiration in 2035 Babesiosis appears in about 10% of Lyme disease cases, and its geographic range is expanding Register now so you can join the live presentation and Q&A. 🔗 Register here: redchip.news/4iA1YV5 #SXTP #60DegreesPharma #Babesiosis #LymeDisease #InfectiousDisease #Biotech #BiotechStocks #NasdaqStocks #InvestorWebinar #SmallCapInvesting